FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 23 filers reported holding FATE THERAPEUTICS INC in Q4 2014. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2018 | $1,000 | – | 100 | 0.0% | 0.00% | – |
| Q1 2018 | $0 | -100.0% | 100 | -60.0% | 0.00% | – |
| Q4 2017 | $1,000 | -75.0% | 250 | -80.0% | 0.00% | – |
| Q3 2017 | $4,000 | 0.0% | 1,250 | 0.0% | 0.00% | – |
| Q2 2017 | $4,000 | -20.0% | 1,250 | 0.0% | 0.00% | – |
| Q1 2017 | $5,000 | +25.0% | 1,250 | -28.6% | 0.00% | – |
| Q4 2016 | $4,000 | -60.0% | 1,750 | -46.2% | 0.00% | – |
| Q3 2016 | $10,000 | -23.1% | 3,250 | -58.1% | 0.00% | – |
| Q2 2016 | $13,000 | +85.7% | 7,750 | +93.8% | 0.00% | – |
| Q1 2016 | $7,000 | +133.3% | 4,000 | +300.0% | 0.00% | – |
| Q4 2015 | $3,000 | -25.0% | 1,000 | 0.0% | 0.00% | – |
| Q1 2015 | $4,000 | +33.3% | 1,000 | +42.9% | 0.00% | – |
| Q4 2014 | $3,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |